[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f6tvEv6VjaT52BB0N5Z5fdV12F66Y56NnD9JjEkpoJDY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":35,"phaseBuckets":36,"rows":43},"Abbott Medical Optics",[4],35,false,0,7,5842,34,[13,16,19,22,25,28,31,33],{"name":14,"count":15},"Cataract",19,{"name":17,"count":18},"Astigmatism",6,{"name":20,"count":21},"Myopia",5,{"name":23,"count":24},"Hyperopia",3,{"name":26,"count":27},"Refractive Error",2,{"name":29,"count":30},"Presbyopia",1,{"name":32,"count":30},"Study Focus is Healthy Contact Lens Wearers",{"name":34,"count":30},"Corneal Staining",[],[37,38,39,40,41,42],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[44,71],{"intervention":45,"totalTrials":30,"cells":46},"(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400",{"EARLY_PHASE1":47,"PHASE1":49,"PHASE2":51,"PHASE3":65,"PHASE4":67,"NA":69},{"trials":48,"activeCount":8},[],{"trials":50,"activeCount":8},[],{"trials":52,"activeCount":8},[53],{"nctId":54,"briefTitle":55,"status":56,"phases":57,"completion":58,"start":59,"enrollment":60,"conditions":61,"interventions":63},"NCT00607776","Artificial Tears Study in Mild to Moderate Dry Eye Patients","COMPLETED",[39],"2007-04","2007-01",110,[62],"Dry Eye",[45,64],"Systane",{"trials":66,"activeCount":8},[],{"trials":68,"activeCount":8},[],{"trials":70,"activeCount":8},[],{"intervention":64,"totalTrials":30,"cells":72},{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":83,"PHASE4":85,"NA":87},{"trials":74,"activeCount":8},[],{"trials":76,"activeCount":8},[],{"trials":78,"activeCount":8},[79],{"nctId":54,"briefTitle":55,"status":56,"phases":80,"completion":58,"start":59,"enrollment":60,"conditions":81,"interventions":82},[39],[62],[45,64],{"trials":84,"activeCount":8},[],{"trials":86,"activeCount":8},[],{"trials":88,"activeCount":8},[]]